PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
14.27%
Revenue growth above 1.5x 3141.T's 6.16%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
9.27%
Gross profit growth at 50-75% of 3141.T's 15.19%. Martin Whitman would question if cost structure or brand is lagging.
16.77%
EBIT growth below 50% of 3141.T's 61.97%. Michael Burry would suspect deeper competitive or cost structure issues.
29.33%
Operating income growth under 50% of 3141.T's 113.57%. Michael Burry would be concerned about deeper cost or sales issues.
31.60%
Net income growth under 50% of 3141.T's 68.89%. Michael Burry would suspect the firm is falling well behind a key competitor.
31.60%
EPS growth under 50% of 3141.T's 68.89%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
31.60%
Diluted EPS growth under 50% of 3141.T's 68.89%. Michael Burry would worry about an eroding competitive position or excessive dilution.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
77.86%
10Y revenue/share CAGR at 50-75% of 3141.T's 148.01%. Martin Whitman would question if the firm’s offerings lag behind the competitor.
81.50%
5Y revenue/share CAGR above 1.5x 3141.T's 49.14%. David Dodd would look for consistent product or market expansions fueling outperformance.
44.91%
3Y revenue/share CAGR similar to 3141.T's 42.27%. Walter Schloss would assume both companies experience comparable short-term cycles.
-100.00%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
149.69%
Below 50% of 3141.T's 378.67%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
103.51%
5Y net income/share CAGR at 75-90% of 3141.T's 129.03%. Bill Ackman would advocate improvements to match competitor’s profit expansion.
27.68%
Below 50% of 3141.T's 65.31%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
198.41%
10Y equity/share CAGR at 75-90% of 3141.T's 253.29%. Bill Ackman would push for either higher ROE or more earnings retention to catch the competitor.
123.92%
5Y equity/share CAGR above 1.5x 3141.T's 55.25%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
56.55%
3Y equity/share CAGR 1.25-1.5x 3141.T's 38.84%. Bruce Berkowitz confirms timely buybacks or margin improvements drive stronger near-term equity growth.
160.87%
Stable or rising dividend while 3141.T is cutting. John Neff sees a strong advantage in consistent shareholder returns vs. a struggling peer.
84.62%
5Y dividend/share CAGR at 50-75% of 3141.T's 145.45%. Martin Whitman might see a lagging policy in mid-term shareholder returns.
33.33%
Below 50% of 3141.T's 68.75%. Michael Burry suspects the firm invests elsewhere or can’t match the competitor’s dividend policy.
-48.82%
Firm’s AR is declining while 3141.T shows 8.66%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
7.60%
We show growth while 3141.T is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
13.64%
Asset growth above 1.5x 3141.T's 3.06%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
5.21%
1.25-1.5x 3141.T's 4.31%. Bruce Berkowitz sees if the firm's capital management strategies surpass the competitor's approach.
63.09%
We have some new debt while 3141.T reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
No Data
No Data available this quarter, please select a different quarter.
-44.38%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.